NEUROCRINE BIOSCIENCES INCNBIXEarnings & Financial Report
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
NBIX Q4 2025 Key Financial Metrics
营收
$805.5M
毛利润
$787.9M
营业利润
$210.9M
净利润
$153.7M
毛利率
97.8%
营业利润率
26.2%
净利率
19.1%
同比增长
28.3%
EPS
$1.49
资金流向
NEUROCRINE BIOSCIENCES INC Q4 2025 Financial Summary
NEUROCRINE BIOSCIENCES INC reported revenue of $805.5M (up 28.3% YoY) for Q4 2025, with a net profit of $153.7M (up 49.1% YoY) (19.1% margin). Cost of goods sold was $17.6M, operating expenses totaled $577.0M.
Key Financial Metrics
| Total Revenue | $805.5M |
|---|---|
| Net Profit | $153.7M |
| Gross Margin | 97.8% |
| Operating Margin | 26.2% |
| Report Period | Q4 2025 |
Revenue Breakdown
NEUROCRINE BIOSCIENCES INC Q4 2025 revenue of $805.5M breaks down across 4 segments, led by INGREZZA Net Product Sales at $653.8M (81.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| INGREZZA Net Product Sales | $653.8M | 81.2% |
| CRENESSITY Net Product Sales | $135.4M | 16.8% |
| Other Income | $12.6M | 1.6% |
| Collaboration Revenue | $7.2M | 0.9% |
NEUROCRINE BIOSCIENCES INC Revenue by Segment — Quarterly Trend
NEUROCRINE BIOSCIENCES INC revenue by segment across the last 4 reported quarters, showing how each business line (such as INGREZZA Net Product Sales and CRENESSITY Net Product Sales) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| INGREZZA Net Product Sales | $653.8M | $686.6M | $624.4M | $545.2M |
| CRENESSITY Net Product Sales | $135.4M | $98.1M | $53.2M | $14.5M |
| Other Income | $12.6M | $10.2M | $9.9M | $12.9M |
| Collaboration Revenue | $7.2M | $5.0M | $5.5M | — |
NEUROCRINE BIOSCIENCES INC Annual Revenue by Year
NEUROCRINE BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B). Click any linked year to see what changed vs the prior 10-K.
NEUROCRINE BIOSCIENCES INC Quarterly Revenue & Net Profit History
NEUROCRINE BIOSCIENCES INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $805.5M | +28.3% | $153.7M | 19.1% |
| Q3 2025 | $794.9M | +27.8% | $209.5M | 26.4% |
| Q2 2025 | $687.5M | +16.5% | $107.5M | 15.6% |
| Q1 2025 | $572.6M | +11.1% | $7.9M | 1.4% |
| Q4 2024 | $627.7M | +21.8% | $103.1M | 16.4% |
| Q3 2024 | $622.1M | +24.7% | $129.8M | 20.9% |
| Q2 2024 | $590.2M | +30.4% | $65.0M | 11.0% |
| Q1 2024 | $515.3M | +22.6% | $43.4M | 8.4% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $515.3M | $590.2M | $622.1M | $627.7M | $572.6M | $687.5M | $794.9M | $805.5M |
| 同比增长 | 22.6% | 30.4% | 24.7% | 21.8% | 11.1% | 16.5% | 27.8% | 28.3% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $3.47B | $3.31B | $3.54B | $3.72B | $3.69B | $3.89B | $4.27B | $4.63B |
| 总负债 | $1.09B | $795.8M | $816.1M | $1.13B | $1.15B | $1.20B | $1.26B | $1.38B |
| 股东权益 | $2.39B | $2.51B | $2.72B | $2.59B | $2.54B | $2.69B | $3.00B | $3.25B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $130.3M | $64.6M | $158.0M | $242.5M | $64.8M | $102.0M | $227.5M | $388.4M |